Stay updated with breaking news from Cascade Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and AstraZeneca Thursday said results from the Phase 3 study of tezepelumab in severe asthma patients, dubbed Navigator, have been published in the New England